Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Avenger Bio Insecticide

Mike Tyson named his knockout of Larry Holmes as his GOAT knockout because he got to avenge Muhammad Ali 🔥 LINK IN BIO FOR FULL EPISODE OF …

avengebio (@AvengeBio) / X

Brendan McLaughlin - Process Development & Manufacturing Scientist - Avenge Bio

Aadhar Mahajan - Project Management at Avenge Bio

Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…

Commercialization Highlights, Office of Technology Transfer, Office of Research

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Reality of Rare Diseases: A Unique Perspective About Rare Diseases

BioDome Group

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

Michael Heffernan

Avenge Bio Appoints Douglas Carlson as Chief Operating and Financial Officer

How far would YOU go to avenge a friend? 😈 Details on this insane story at link in bio, link in Stories, or go here:…